# Omega-3 Supplementation to ADHD Medication in Children

> **NCT02204410** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 21 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Deficient Emotional Self-Regulation

## Interventions

- **DIETARY_SUPPLEMENT:** Omega-3 Fatty Acid
- **DRUG:** ADHD Medication

## Key facts

- **NCT ID:** NCT02204410
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204410, "Omega-3 Supplementation to ADHD Medication in Children". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02204410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*